Can Ivermectin and Mebendazole Treat Cancer?

Key Takeaways

• Study used only patient‑reported outcomes, no clinical verification.
• No control group; baseline 63% already had non‑progressing disease.
• 38% of participants dropped out, creating attrition bias.
• Dosage (25 mg ivermectin, 250 mg mebendazole) far exceeds FDA label.
• Authors labeled project as quality improvement to bypass IRB review.

Pulse Analysis

Repurposing antiparasitic drugs such as ivermectin and mebendazole for oncology has attracted attention from fringe promoters, but credible evidence remains scarce. The Wellness Company’s recent report, circulated widely on social media, attempts to position its compounded capsule as a breakthrough cancer therapy. By collecting baseline and six‑month data exclusively through electronic surveys, the study sidestepped the rigorous imaging, pathology, and physician assessments that define modern oncology trials. The absence of a comparator group and the reliance on patient‑self‑assessment undermine any claim of efficacy, turning headline‑grabbing percentages into speculative signals at best.

Beyond the scientific shortcomings, the study raises serious regulatory red flags. The dosage regimen—25 mg of ivermectin and 250 mg of mebendazole daily for up to six months—far exceeds the FDA‑approved labeling for parasitic infections, a scenario that typically triggers an Investigational New Drug (IND) requirement. By labeling the work as a quality‑improvement initiative, the authors effectively sidestepped Institutional Review Board review, despite the project’s clear aim to generate generalizable knowledge about a new indication. This classification conflicts with federal definitions of human subjects research and may place the company outside both Common Rule and FDA oversight, leaving participants without formal protections.

For clinicians and patients navigating a landscape saturated with unverified cancer cures, the takeaway is caution. While anecdotal reports can spark hypotheses, they cannot substitute for randomized, controlled trials that verify safety and benefit. Regulatory agencies, professional societies, and tele‑health platforms must enforce stricter standards for off‑label compounding and ensure that any investigational use undergoes proper ethical review. Until robust data emerge, the ivermectin‑mebendazole combination should remain a laboratory curiosity rather than a treatment option for cancer patients.